Sort by
Items per page

Send to

Choose Destination


Stimulation of breast cancer cell lines by post-surgical drainage fluids. Ramolu L et al. Anticancer Res. (2014)

Local anesthetics induce apoptosis in human breast tumor cells. Chang YC et al. Anesth Analg. (2014)

Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy. Koren S et al. Mol Cell. (2015)

Search results

Items: 1 to 20 of 166

  • Showing results for a modified search because your search retrieved no results.

α-Tocopherol succinate enhances pterostilbene anti-tumor activity in human breast cancer cells <i>in vivo</i> and <i>in vitro</i>.

Tam KW, Ho CT, Tu SH, Lee WJ, Huang CS, Chen CS, Wu CH, Lee CH, Ho YS.

Oncotarget. 2017 Dec 17;9(4):4593-4606. doi: 10.18632/oncotarget.23390. eCollection 2018 Jan 12.


[Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].

Li MJ, Li HR, Cheng X, Bi R, Tu XY, Liu F, Chen LH.

Zhonghua Fu Chan Ke Za Zhi. 2017 Dec 25;52(12):835-843. doi: 10.3760/cma.j.issn.0529-567x.2017.12.008. Chinese.


miR-34a expression in human breast cancer is associated with drug resistance.

Li ZH, Weng X, Xiong QY, Tu JH, Xiao A, Qiu W, Gong Y, Hu EW, Huang S, Cao YL.

Oncotarget. 2017 Nov 6;8(63):106270-106282. doi: 10.18632/oncotarget.22286. eCollection 2017 Dec 5.


The expression of VE-cadherin in breast cancer cells modulates cell dynamics as a function of tumor differentiation and promotes tumor-endothelial cell interactions.

Rezaei M, Cao J, Friedrich K, Kemper B, Brendel O, Grosser M, Adrian M, Baretton G, Breier G, Schnittler HJ.

Histochem Cell Biol. 2018 Jan;149(1):15-30. doi: 10.1007/s00418-017-1619-8. Epub 2017 Nov 15.


Inhibition of miR-155, a therapeutic target for breast cancer, prevented in cancer stem cell formation.

Zuo J, Yu Y, Zhu M, Jing W, Yu M, Chai H, Liang C, Tu J.

Cancer Biomark. 2018 Feb 6;21(2):383-392. doi: 10.3233/CBM-170642.


Long non-coding RNA 657 suppresses hepatocellular carcinoma cell growth by acting as a molecular sponge of miR-106a-5p to regulate PTEN expression.

Hu B, Cai H, Zheng R, Yang S, Zhou Z, Tu J.

Int J Biochem Cell Biol. 2017 Nov;92:34-42. doi: 10.1016/j.biocel.2017.09.008. Epub 2017 Sep 14.


Inhibiting MYC binding to the E-box DNA motif by ME47 decreases tumour xenograft growth.

Lustig LC, Dingar D, Tu WB, Lourenco C, Kalkat M, Inamoto I, Ponzielli R, Chan WCW, Shin JA, Penn LZ.

Oncogene. 2017 Dec 7;36(49):6830-6837. doi: 10.1038/onc.2017.275. Epub 2017 Aug 14.


New dinuclear palladium(II) complexes: Studies of the nucleophilic substitution reactions, DNA/BSA interactions and cytotoxic activity.

Ćoćić D, Jovanović S, Nišavić M, Baskić D, Todorović D, Popović S, Bugarčić ŽD, Petrović B.

J Inorg Biochem. 2017 Oct;175:67-79. doi: 10.1016/j.jinorgbio.2017.07.009. Epub 2017 Jul 16.


A rapid and quantitative method to detect human circulating tumor cells in a preclinical animal model.

Tu SH, Hsieh YC, Huang LC, Lin CY, Hsu KW, Hsieh WS, Chi WM, Lee CH.

BMC Cancer. 2017 Jun 23;17(1):440. doi: 10.1186/s12885-017-3419-x.


Effectiveness of computer-aided diagnosis (CADx) of breast pathology using immunohistochemistry results of core needle biopsy samples for synaptophysin, oestrogen receptor and CK14/p63 for classification of epithelial proliferative lesions of the breast.

Maeda I, Kubota M, Ohta J, Shinno K, Tajima S, Ariizumi Y, Doi M, Oana Y, Kanemaki Y, Tsugawa K, Ueno T, Takagi M.

J Clin Pathol. 2017 Dec;70(12):1057-1062. doi: 10.1136/jclinpath-2017-204478. Epub 2017 Jun 19.


Construction and expression of a lentivirus expression vector carrying the VEGF165-EGFP fusion gene in breast cancer MCF-7 cells.

Luo M, Huang H, Hou L, Shao S, Huang S, Zhao X.

Oncol Lett. 2017 Mar;13(3):1745-1752. doi: 10.3892/ol.2017.5601. Epub 2017 Jan 17.


Tumor Suppressor PTPRJ Is a Target of miR-155 in Colorectal Cancer.

Zhang XF, Tu R, Li K, Ye P, Cui X.

J Cell Biochem. 2017 Oct;118(10):3391-3400. doi: 10.1002/jcb.25995. Epub 2017 May 3.


Lymphocyte-specific protein 1 inhibits the growth of hepatocellular carcinoma by suppressing ERK1/2 phosphorylation.

Zhang H, Wang Y, Liu Z, Yao B, Dou C, Xu M, Li Q, Jia Y, Wu S, Tu K, Liu Q.

FEBS Open Bio. 2016 Nov 7;6(12):1227-1237. doi: 10.1002/2211-5463.12139. eCollection 2016 Dec.


Nuclear Drosha enhances cell invasion via an EGFR-ERK1/2-MMP7 signaling pathway induced by dysregulated miRNA-622/197 and their targets LAMC2 and CD82 in gastric cancer.

Xu L, Hou Y, Tu G, Chen Y, Du YE, Zhang H, Wen S, Tang X, Yin J, Lang L, Sun K, Yang G, Tang X, Liu M.

Cell Death Dis. 2017 Mar 2;8(3):e2642. doi: 10.1038/cddis.2017.5.


Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.

Heimes AS, Madjar K, Edlund K, Battista MJ, Almstedt K, Gebhard S, Foersch S, Rahnenführer J, Brenner W, Hasenburg A, Hengstler JG, Schmidt M.

J Cancer Res Clin Oncol. 2017 Jul;143(7):1123-1131. doi: 10.1007/s00432-017-2377-7. Epub 2017 Mar 1.


Uncovering the roles of long non-coding RNAs in cancer stem cells.

Huang X, Xiao R, Pan S, Yang X, Yuan W, Tu Z, Xu M, Zhu Y, Yin Q, Wu Y, Hu W, Shao L, Xiong J, Zhang Q.

J Hematol Oncol. 2017 Feb 28;10(1):62. doi: 10.1186/s13045-017-0428-9. Review.


Annexin A1 influences in breast cancer: Controversies on contributions to tumour, host and immunoediting processes.

Tu Y, Johnstone CN, Stewart AG.

Pharmacol Res. 2017 May;119:278-288. doi: 10.1016/j.phrs.2017.02.011. Epub 2017 Feb 14. Review.


Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.

Li M, Li H, Liu F, Bi R, Tu X, Chen L, Ye S, Cheng X.

J Ovarian Res. 2017 Feb 10;10(1):9. doi: 10.1186/s13048-017-0304-9.


MiR-214 negatively regulates proliferation and WNT/β-catenin signaling in breast cancer.

Yi SJ, Li LL, Tu WB.

Eur Rev Med Pharmacol Sci. 2016 Dec;20(24):5148-5154.


Epsin Family Member 3 and Ribosome-Related Genes Are Associated with Late Metastasis in Estrogen Receptor-Positive Breast Cancer and Long-Term Survival in Non-Small Cell Lung Cancer Using a Genome-Wide Identification and Validation Strategy.

Hellwig B, Madjar K, Edlund K, Marchan R, Cadenas C, Heimes AS, Almstedt K, Lebrecht A, Sicking I, Battista MJ, Micke P, Schmidt M, Hengstler JG, Rahnenführer J.

PLoS One. 2016 Dec 7;11(12):e0167585. doi: 10.1371/journal.pone.0167585. eCollection 2016.

Supplemental Content

Loading ...
Support Center